These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 11561807)

  • 21. In vitro activity of ABT-773, telithromycin and eight other antimicrobials against erythromycin-resistant Streptococcus pneumoniae respiratory isolates of children.
    Johnson CN; Benjamin WH; Gray BM; Crain MC; Edwards KM; Waites KB
    Int J Antimicrob Agents; 2001 Dec; 18(6):531-5. PubMed ID: 11738340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Susceptibility to telithromycin in 1,011 Streptococcus pyogenes isolates from 10 central and Eastern European countries.
    Nagai K; Appelbaum PC; Davies TA; Kelly LM; Hoellman DB; Andrasevic AT; Drukalska L; Hryniewicz W; Jacobs MR; Kolman J; Miciuleviciene J; Pana M; Setchanova L; Thege MK; Hupkova H; Trupl J; Urbaskova P
    Antimicrob Agents Chemother; 2002 Feb; 46(2):546-9. PubMed ID: 11796375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species.
    Jalava J; Kataja J; Seppälä H; Huovinen P
    Antimicrob Agents Chemother; 2001 Mar; 45(3):789-93. PubMed ID: 11181362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
    Walsh F; Carnegy F; Willcock J; Amyes S
    J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activities of cethromycin (ABT-773), a new ketolide, against Streptococcus pneumoniae strains that are not susceptible to penicillin or macrolides.
    Mason EO; Lamberth LB; Wald ER; Bradley JS; Barson WJ; Kaplan SL
    Antimicrob Agents Chemother; 2003 Jan; 47(1):166-9. PubMed ID: 12499186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Susceptibilities of 228 penicillin- and erythromycin-susceptible and -resistant pneumococci to RU 64004, a new ketolide, compared with susceptibilities to 16 other agents.
    Ednie LM; Spangler SK; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1997 May; 41(5):1033-6. PubMed ID: 9145864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro susceptibility of gram-positive cocci isolated from skin and respiratory tract to azithromycin and twelve other antimicrobial agents.
    Mendes CM; Sinto SI; Oplustil CP;
    Braz J Infect Dis; 2001 Oct; 5(5):269-76. PubMed ID: 11779453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CEM-101 activity against Gram-positive organisms.
    Woosley LN; Castanheira M; Jones RN
    Antimicrob Agents Chemother; 2010 May; 54(5):2182-7. PubMed ID: 20176910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test, and disk diffusion methodologies.
    Davies TA; Kelly LM; Jacobs MR; Appelbaum PC
    J Clin Microbiol; 2000 Apr; 38(4):1444-8. PubMed ID: 10747123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activities of a new ketolide, ABT-773, against multidrug-resistant gram-positive cocci.
    Singh KV; Malathum K; Murray BE
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3640-3. PubMed ID: 11709359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antistreptococcal activity of telithromycin compared with seven other drugs in relation to macrolide resistance mechanisms in Russia.
    Kozlov RS; Bogdanovitch TM; Appelbaum PC; Ednie L; Stratchounski LS; Jacobs MR; Bozdogan B
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2963-8. PubMed ID: 12183254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 Pneumococci from 10 central and Eastern European countries.
    Nagai K; Appelbaum PC; Davies TA; Kelly LM; Hoellman DB; Andrasevic AT; Drukalska L; Hryniewicz W; Jacobs MR; Kolman J; Miciuleviciene J; Pana M; Setchanova L; Thege MK; Hupkova H; Trupl J; Urbaskova P
    Antimicrob Agents Chemother; 2002 Feb; 46(2):371-7. PubMed ID: 11796344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial activity of RU-66647, a new ketolide.
    Jones RN; Biedenbach DJ
    Diagn Microbiol Infect Dis; 1997; 27(1-2):7-12. PubMed ID: 9127099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Multicenter study in southern South America of the in vitro activity of telithromycin in strains with defined resistance phenotypes isolated from community-acquired respiratory infections].
    Casellas JM; Visser M; Mac Dougall N; Coco B; Tomé G; Gliosca L;
    Rev Esp Quimioter; 2001 Sep; 14(3):269-74. PubMed ID: 11753448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Streptococcus pyogenes isolates with characterized macrolide resistance mechanisms in Spain: in vitro activities of telithromycin and cethromycin.
    Morosini MI; Cantón R; Loza E; del Campo R; Almaraz F; Baquero F
    J Antimicrob Chemother; 2003 Jul; 52(1):50-5. PubMed ID: 12805254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disposition of oral telithromycin in foals and in vitro activity of the drug against macrolide-susceptible and macrolide-resistant Rhodococcus equi isolates.
    Javsicas LH; Giguère S; Womble AY
    J Vet Pharmacol Ther; 2010 Aug; 33(4):383-8. PubMed ID: 20646201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of telithromycin and seven other agents against 1034 pediatric Streptococcus pneumoniae isolates from ten central and eastern European centers.
    Bozdogan B; Appelbaum PC; Kelly LM; Hoellman DB; Tambic-Andrasevic A; Drukalska L; Hryniewicz W; Hupkova H; Jacobs MR; Kolman J; Konkoly-Thege M; Miciuleviciene J; Pana M; Setchanova L; Trupl J; Urbaskova P
    Clin Microbiol Infect; 2003 Jul; 9(7):653-61. PubMed ID: 12925106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae.
    Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2000 Feb; 44(2):414-7. PubMed ID: 10639373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria.
    Schülin T; Wennersten CB; Moellering RC; Eliopoulos GM
    Antimicrob Agents Chemother; 1997 May; 41(5):1196-202. PubMed ID: 9145901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparative antimicrobial activity of RP 59,500 (quinupristin-dalfopristin), the first semisynthetic injectable streptgramin, against gram-positive cocci and other recent clinical pathogens].
    Nakashio S; Iwasawa H; Iino S; Shimada J
    Jpn J Antibiot; 1997 Oct; 50(10):844-53. PubMed ID: 9412874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.